Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
20
BIXT Quote, Financials, Valuation and Earnings
Last price:
$0.1000
Seasonality move
:
70.39%
Day range:
$0.0943 - $0.1020
52-week range:
$0.0615 - $0.2283
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
53.82x
P/B ratio:
--
Volume:
27K
Avg. volume:
95.5K
1-year change:
8.31%
Market cap:
$8.6M
Revenue:
--
EPS (TTM):
-$0.04
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bioxytran has -- downside to fair value with a price target of -- per share.
BIXT vs. S&P 500
-
Over the past 5 trading days, Bioxytran has underperformed the S&P 500 by -4.8% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioxytran does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioxytran has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bioxytran reported revenues of --.
Earnings Growth
-
Bioxytran earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bioxytran reported earnings per share of -$0.02.
Enterprise value:
9.9M
EV / Invested capital:
--
Price / LTM sales:
53.82x
EV / EBIT:
--
EV / Revenue:
45.50x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-72.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$2.4M | -$3.8M | -$2M | -$781.3K | -$517K | |
| EBITDA | -$2.2M | -$3.8M | -$2.1M | -$544K | -$1.3M | |
| Diluted EPS | -$0.03 | -$0.02 | -$0.04 | -- | -$0.02 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $366.4K | $739.6K | $153.8K | $10K | $4.4K | |
| Total Assets | $385.3K | $807.9K | $233.5K | $125.5K | $136.1K | |
| Current Liabilities | $2.9M | $4.9M | $4.3M | $1.1M | $2.8M | |
| Total Liabilities | $2.9M | $4.9M | $4.3M | $1.1M | $2.8M | |
| Total Equity | -$2.5M | -$4.1M | -$4.1M | -$990.4K | -$2.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.3M | -$698.1K | -$113.5K | -$109.6K | -$167.3K | |
| Cash From Investing | -$14.6K | -$45.6K | -$22.2K | -$6K | -$20 | |
| Cash From Financing | $728K | $599.9K | $130K | $99.5K | $166.5K | |
| Free Cash Flow | -$1.3M | -$743.6K | -$135.7K | -$115.6K | -$167.3K | |
BIXT
Sector
Market Cap
$8.6M
$34.4M
Price % of 52-Week High
42.23%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
13.95%
-37.36%
Beta (5-Year)
1.555
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0988
200-day SMA
Sell
Level
$0.1133
Bollinger Bands (100)
Sell
Level
0.1029 - 0.1629
Chaikin Money Flow
Sell
Level
-6.6M
20-day SMA
Sell
Level
$0.1041
Relative Strength Index (RSI14)
Sell
Level
38.6689
ADX Line
Sell
Level
29.0382
Williams %R
Neutral
Level
-74.744
50-day SMA
Sell
Level
$0.1220
MACD (12, 26)
Sell
Level
-0.0077
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-2.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.
Stock Forecast FAQ
In the current month, BIXT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIXT average analyst price target in the past 3 months is --.
-
Where Will Bioxytran Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioxytran share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Bioxytran?
Analysts are divided on their view about Bioxytran share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bioxytran is a Sell and believe this share price will rise from its current level to --.
-
What Is Bioxytran's Price Target?
The price target for Bioxytran over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIXT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioxytran is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BIXT?
You can purchase shares of Bioxytran via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioxytran shares.
-
What Is The Bioxytran Share Price Today?
Bioxytran was last trading at $0.1000 per share. This represents the most recent stock quote for Bioxytran. Yesterday, Bioxytran closed at $0.0964 per share.
-
How To Buy Bioxytran Stock Online?
In order to purchase Bioxytran stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
